These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 12833105)

  • 1. Paring down the company: the effect of consolidation in the European biotech sector.
    Bassett P
    Nat Biotechnol; 2003 Jul; 21(7):829-30. PubMed ID: 12833105
    [No Abstract]   [Full Text] [Related]  

  • 2. Biotech parks proliferate, despite concerns over sustainability.
    Jia H; Jayaraman KS; Orellana C
    Nat Biotechnol; 2003 Nov; 21(11):1259-60. PubMed ID: 14595344
    [No Abstract]   [Full Text] [Related]  

  • 3. Navigating the European biotechnology association labyrinth: A commentary on the role of biotechnology associations, selecting the most appropriate ones, and why now is the time to join.
    Suojanen C
    N Biotechnol; 2010 May; 27(2):95-9. PubMed ID: 20211280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of biotech clusters questioned.
    Sheridan C
    Nat Biotechnol; 2003 Nov; 21(11):1258-9. PubMed ID: 14595343
    [No Abstract]   [Full Text] [Related]  

  • 5. Supplying the health-care explosion.
    Bienias T
    Med Device Technol; 2001 Dec; 12(10):14-5. PubMed ID: 15966138
    [No Abstract]   [Full Text] [Related]  

  • 6. Outsourcing manufacturing.
    Strauss L; Geimer H
    Med Device Technol; 2001 Dec; 12(10):10-3. PubMed ID: 15966137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leadership management needs in evolving biotech companies.
    Föller A
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE64-6. PubMed ID: 12089593
    [No Abstract]   [Full Text] [Related]  

  • 8. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 9. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 10. Too little, too late: when is the right time for new leadership in biotech?
    Branthwaite P; Williams SJ
    Nat Biotechnol; 2004 Apr; 22(4):487-8. PubMed ID: 15034591
    [No Abstract]   [Full Text] [Related]  

  • 11. Brazilian health biotech--fostering crosstalk between public and private sectors.
    Rezaie R; Frew SE; Sammut SM; Maliakkal MR; Daar AS; Singer PA
    Nat Biotechnol; 2008 Jun; 26(6):627-44. PubMed ID: 18536682
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of Business Models in Funding the Biotech Industry: Global Trends and Challenges for Cuban Biotechnology.
    Blanco-García E
    MEDICC Rev; 2020 Jan; 22(1):11-16. PubMed ID: 32327617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Splurge or merge?
    Jacobs T
    Nat Biotechnol; 2003 May; 21(5):485. PubMed ID: 12721563
    [No Abstract]   [Full Text] [Related]  

  • 14. Marriage guidance for collaborators.
    Hogan J
    Med Device Technol; 2005 Mar; 16(2):25-6. PubMed ID: 15828497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. France to focus on a few biotech clusters.
    Balcon E
    Nat Biotechnol; 2004 Sep; 22(9):1063-4. PubMed ID: 15340457
    [No Abstract]   [Full Text] [Related]  

  • 16. Reinventing the biotech manager.
    Li J; Halal WE
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE61-3. PubMed ID: 12089592
    [No Abstract]   [Full Text] [Related]  

  • 17. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 18. Biotechnology financing dilemmas and the role of special purpose entities.
    Schiff L; Murray F
    Nat Biotechnol; 2004 Mar; 22(3):271-7. PubMed ID: 14990945
    [No Abstract]   [Full Text] [Related]  

  • 19. Partnering for better microbial diagnostics.
    Perkins MD; Small PM
    Nat Biotechnol; 2006 Aug; 24(8):919-21. PubMed ID: 16900130
    [No Abstract]   [Full Text] [Related]  

  • 20. More than the sum of their parts? Clustering is becoming more prevalent in the biosciences, despite concerns over the sustainability and economic effectiveness of science parks and hubs.
    Rinaldi A
    EMBO Rep; 2006 Feb; 7(2):133-6. PubMed ID: 16452923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.